Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker.
Prediction models are increasingly used to complement clinical reasoning and decision making in modern medicine in general, and in the cardiovascular domain in particular. Developed models first and foremost need to provide accurate and (internally and externally) validated estimates of probabilitie...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797105129638330368 |
|---|---|
| author | Moons, K Kengne, A Woodward, M Royston, P Vergouwe, Y Altman, D Grobbee, D |
| author_facet | Moons, K Kengne, A Woodward, M Royston, P Vergouwe, Y Altman, D Grobbee, D |
| author_sort | Moons, K |
| collection | OXFORD |
| description | Prediction models are increasingly used to complement clinical reasoning and decision making in modern medicine in general, and in the cardiovascular domain in particular. Developed models first and foremost need to provide accurate and (internally and externally) validated estimates of probabilities of specific health conditions or outcomes in targeted patients. The adoption of such models must guide physician's decision making and an individual's behaviour, and consequently improve individual outcomes and the cost-effectiveness of care. In a series of two articles we review the consecutive steps generally advocated for risk prediction model research. This first article focuses on the different aspects of model development studies, from design to reporting, how to estimate a model's predictive performance and the potential optimism in these estimates using internal validation techniques, and how to quantify the added or incremental value of new predictors or biomarkers (of whatever type) to existing predictors. Each step is illustrated with empirical examples from the cardiovascular field. |
| first_indexed | 2024-03-07T06:43:08Z |
| format | Journal article |
| id | oxford-uuid:f9f8ba95-61b7-4bbe-957b-9aafd3e101d6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:43:08Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:f9f8ba95-61b7-4bbe-957b-9aafd3e101d62022-03-27T13:02:05ZRisk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f9f8ba95-61b7-4bbe-957b-9aafd3e101d6EnglishSymplectic Elements at Oxford2012Moons, KKengne, AWoodward, MRoyston, PVergouwe, YAltman, DGrobbee, DPrediction models are increasingly used to complement clinical reasoning and decision making in modern medicine in general, and in the cardiovascular domain in particular. Developed models first and foremost need to provide accurate and (internally and externally) validated estimates of probabilities of specific health conditions or outcomes in targeted patients. The adoption of such models must guide physician's decision making and an individual's behaviour, and consequently improve individual outcomes and the cost-effectiveness of care. In a series of two articles we review the consecutive steps generally advocated for risk prediction model research. This first article focuses on the different aspects of model development studies, from design to reporting, how to estimate a model's predictive performance and the potential optimism in these estimates using internal validation techniques, and how to quantify the added or incremental value of new predictors or biomarkers (of whatever type) to existing predictors. Each step is illustrated with empirical examples from the cardiovascular field. |
| spellingShingle | Moons, K Kengne, A Woodward, M Royston, P Vergouwe, Y Altman, D Grobbee, D Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. |
| title | Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. |
| title_full | Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. |
| title_fullStr | Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. |
| title_full_unstemmed | Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. |
| title_short | Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. |
| title_sort | risk prediction models i development internal validation and assessing the incremental value of a new bio marker |
| work_keys_str_mv | AT moonsk riskpredictionmodelsidevelopmentinternalvalidationandassessingtheincrementalvalueofanewbiomarker AT kengnea riskpredictionmodelsidevelopmentinternalvalidationandassessingtheincrementalvalueofanewbiomarker AT woodwardm riskpredictionmodelsidevelopmentinternalvalidationandassessingtheincrementalvalueofanewbiomarker AT roystonp riskpredictionmodelsidevelopmentinternalvalidationandassessingtheincrementalvalueofanewbiomarker AT vergouwey riskpredictionmodelsidevelopmentinternalvalidationandassessingtheincrementalvalueofanewbiomarker AT altmand riskpredictionmodelsidevelopmentinternalvalidationandassessingtheincrementalvalueofanewbiomarker AT grobbeed riskpredictionmodelsidevelopmentinternalvalidationandassessingtheincrementalvalueofanewbiomarker |